Francois Roubille: New ESC Consensus on Inflammation in Coronary Syndromes
Francois Roubille, Head of the Intensive Care Unit at University Hospital of Montpellier, shared a post on LinkedIn:
”New ESC consensus on inflammation in coronary syndromes!
Proud to share our new clinical consensus statement on inflammation in coronary syndromes, published in European Heart Journal: Acute Cardiovascular Care, on behalf of several ESC councils and working groups.
doi: 10.1093/ehjacc/zuag086
We review how inflammation drives the continuum from chronic coronary syndromes to acute coronary syndromes, integrating mechanisms, biomarkers, imaging, and clinical implications.
Key messages include:
- Inflammation is a modifiable but secondary driver of risk in coronary artery disease.
- High-sensitivity CRP is the most practical biomarker for routine clinical use.
- Inflammation assessment should never delay guideline-directed revascularization and prevention.
- Standard therapies and lifestyle changes already exert meaningful anti-inflammatory effects.
- Low-dose colchicine is currently the only widely implementable anti-inflammatory drug in everyday practice, in carefully selected patients.
Beyond summarizing the evidence, the document provides pragmatic guidance on when, how, and in whom to assess and treat inflammation in real-world clinical practice, emphasizing a holistic, patient-centred approach rather than an ‘inflammation-only’ strategy.
I hope this consensus will help colleagues integrate inflammation into coronary care in a balanced way – bridging mechanistic insights, trial data, and daily decision-making.”
Stay updated with Hemostasis Today.
-
Aug 16, 2026, 13:53Honey Blankenship: United by a Shared Commitment to the Bleeding Disorders Community
-
Aug 16, 2026, 13:46Sagar Bejalwar: A Rare Bleeding Disorder and the Importance of Specialized Care
-
Aug 16, 2026, 13:39Sharun Khan: Advancing Regenerative Medicine Through Veterinary Translational Science
-
Aug 16, 2026, 13:05Neil Morgan: Submit Your Abstract for BSHT 2027
-
Aug 16, 2026, 12:50Heba Youssef: Can Cefoperazone Cause Coagulopathy?
-
Aug 16, 2026, 12:35Mohammad Alkhalil: Stroke Remains a Dreaded Complication in TAVI
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process